Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antithrombin-III for PVT Prevention in Cirrhosis (PiVoT-AC)
NCT04055389Phase 1Withdrawn
- Start
- Jan 2021
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in portal vein thrombosis (PVT) comparing AT-III treatment with Placebo (2 arms). Primary endpoint: Development of de Novo Portal Vein Thrombosis at 72 weeks. Planned start Jan 2021; status: withdrawn.
02
Drugs
antithrombin III
03
Conditions
portal vein thrombosis (PVT)
Beyond the preview
Go deeper on NCT04055389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055389.